store at low temperature
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Rosiglitazone (BRL49653) is a PPARγ agonist, TRPC5 activator, and TRPM3 inhibitor with oral activity. Rosiglitazone is also a hypoglycemic agent and a thiazolidinedione insulin sensitizer.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
25 mg | 在庫あり | ¥ 7,500 | |||
50 mg | 在庫あり | ¥ 11,000 | |||
100 mg | 在庫あり | ¥ 19,000 | |||
200 mg | 在庫あり | ¥ 34,000 | |||
500 mg | 在庫あり | ¥ 56,500 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 12,000 |
説明 | Rosiglitazone (BRL49653) is a PPARγ agonist, TRPC5 activator, and TRPM3 inhibitor with oral activity. Rosiglitazone is also a hypoglycemic agent and a thiazolidinedione insulin sensitizer. |
ターゲット&IC50 | PPARγ2:100 nM(EC50), PPARγ:60 nM(EC50), PPARγ1:30 nM(EC50) |
In vitro | Rosiglitazone reduces bone formation rate and increases adipose content within the bone marrow. It decreases the expression of osteoblast-specific genes Runx2/Cbfa1, DLX5, and α1(I) collagen, while expression of the adipocyte-specific fatty acid binding protein AP2 is increased. This drug leads to significant bone loss, evidenced by reductions in bone mass, trabecular width, and number, along with an increase in trabecular separation. Furthermore, in ob/ob mice, rosiglitazone enhances transcription of genes encoding mitochondrial proteins in white adipocytes, which is accompanied by changes in mitochondrial number and structure. |
In vivo | In certain cell lines, Rosiglitazone reduces cholesterol synthesis independent of peroxisome proliferator-activated receptor γ (PPARγ). The compound significantly enhances the phosphorylation of threonine 172 in the α subunit of AMP-dependent protein kinase, increasing the AMP: ATP ratio. Additionally, Rosiglitazone boosts secretion of adiponectin by up to 2.3-fold from omental cells, while secretion from subcutaneous fat cells remains unaffected. In 3T3-L1 adipocytes, Rosiglitazone alters mitochondrial morphological characteristics and protein profile. It activates complexes containing α1- and α2-AMPK, leading to a marked increase in phosphorylation of acetyl-CoA carboxylase. Rosiglitazone also acts as a dominant inhibitor of osteoblastogenesis from mouse marrow in vitro through the activation of PPAR-gamma2. |
細胞研究 | Rosiglitazone is dissolved in DMSO and stored, and then diluted with appropriate medium before use[2]. Human neuroblastoma SH-SY5Y cells are maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum, 100 μg/mL Streptomycin and 100 U/mL Penicillin G. SH-SY5Y cells are transfected with the longest isoform of human tau (2N4R) tagged with GFP using lipofectamine. 24 hr after transfection, cells are treated with Rosiglitazone (10 μM, 50 μM) for 24 hr[2]. |
別名 | BRL49653 |
分子量 | 357.43 |
分子式 | C18H19N3O3S |
CAS No. | 122320-73-4 |
store at low temperature
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
1eq. HCl: 35.7 mg/mL (100 mM)
DMSO: 45 mg/mL (125.9 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Rosiglitazone 122320-73-4 Apoptosis Autophagy DNA Damage/DNA Repair Membrane transporter/Ion channel Metabolism Ferroptosis TRP/TRPV Channel PPAR diabetic neuroprotection senescence PPARγ Inhibitor cancer diabetes BRL-49653 HCC antihyperglycemic TRP Channel bladder mellitus Peroxisome proliferator-activated receptors inhibit BRL49653 BRL 49653 carcinoma smoke ovarian cancer Transient receptor potential channels hepatocellular inhibitor